ReviewClinical cancer research : an official journal of the American Association for Cancer Research2016
Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy.
Review in Clinical cancer research : an official journal of the American Association for Cancer Research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03792724 (Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid Tumors), which is not on this map. Cited by 153 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid Tumors
Who cites it
153 citing papers in PubMed, 1 synthesis or guideline pooled it, 261 citations in OpenAlex.
- The Emerging World of TCR-T Cell Trials Against Cancer: A Systematic Review.Technology in cancer research & treatment · 2019Pooled it
- Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma.Journal of hematology & oncology · 2017Trial
- Review
- Metabolic activation using fructose-1,6-bisphosphate microparticles of non-virally LNP-generated CAR-macrophages induces anti-tumor immune responses.Journal of materials chemistry. B · 2026Article
- Cellular therapies in systemic lupus erythematosus: recent progress and future directions.Clinical rheumatology · 2026Review
- The Role of Mesothelin in Gynecological Tumors and Its Significance in Targeted Therapies-A Review.Cancers · 2026Review
- Immunotherapy in NK/T-Cell Lymphoma: Mechanisms, Clinical Evidence, Resistance, and Emerging Multimodal Strategies.Cancers · 2026Review
- Development of tri-cistronic CLDN18.2 CAR-T cells incorporating PD-1/CD28 switch and cyclophilin A for enhanced solid tumor immunotherapy.Journal of microbiology (Seoul, Korea) · 2026Article
- Introduction to the Immune System.Methods in molecular biology (Clifton, N.J.) · 2026Review
- Skin Reactions and Other Underappreciated Dermatologic Side Effects of Cancer Therapies.Current treatment options in oncology · 2025Review
- GPR65 Inactivation in Tumor Cells Drives Antigen-Independent CAR T-cell Resistance via Macrophage Remodeling.Cancer discovery · 2025Article
- Cancer immunotherapy insights: key takeaways from the ADSCC bone marrow and cellular therapy congress 2024.Frontiers in immunology · 2025Review
- Predictive model for prognosis, immune microenvironment and drug sensitivity of colon carcinoma based on cuproptosis-related genes.International journal of clinical and experimental pathology · 2025Article
- CAR-T Cell Therapy: Managing Side Effects and Overcoming Challenges.Advanced biomedical research · 2025Review
- First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors.Journal for immunotherapy of cancer · 2024Article
- Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling.Nature cancer · 2024Article
- Genetically Engineered CLDN18.2 CAR-T Cells Expressing Synthetic PD1/CD28 Fusion Receptors Produced Using a Lentiviral Vector.Journal of microbiology (Seoul, Korea) · 2024Article
- CAR-T Cell Therapy in Ovarian Cancer: Where Are We Now?Diagnostics (Basel, Switzerland) · 2024Review
- Emerging strategies to overcome ovarian cancer: advances in immunotherapy.Frontiers in pharmacology · 2024Review
- Case report: CD7-targeted autologous CAR-T therapy for the treatment of T-cell acute lymphoblastic leukemia undergoing allogeneic peripheral blood stem cell transplantation in the long-term follow-up.Frontiers in immunology · 2024Article
93 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Chimeric antigen receptors (CAR) are engineered fusion proteins constructed from antigen recognition, signaling, and costimulatory domains that can be expressed in cytotoxic T cells with the purpose of reprograming the T cells to specifically target tumor cells. CAR T-cell therapy uses gene transfer technology to reprogram a patient's own T cells to stably express CARs, thereby combining the specificity of an antibody with the potent cytotoxic and memory functions of a T cell. In early-phase clinical trials, CAR T cells targeting CD19 have resulted in sustained complete responses within a population of otherwise refractory patients with B-cell malignancies and, more specifically, have shown complete response rates of approximately 90% in patients with relapsed or refractory acute lymphoblastic leukemia. Given this clinical efficacy, preclinical development of CAR T-cell therapy for a number of cancer indications has been actively investigated, and the future of the CAR T-cell field is extensive and dynamic. Several approaches to increase the feasibility and safety of CAR T cells are currently being explored, including investigation into the mechanisms regulating the persistence of CAR T cells. In addition, numerous early-phase clinical trials are now investigating CAR T-cell therapy beyond targeting CD19, especially in solid tumors. Trials investigating combinations of CAR T cells with immune checkpoint blockade therapies are now beginning and results are eagerly awaited. This review evaluates several of the ongoing and future directions of CAR T-cell therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.